---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-21-000213"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2021-10-26T23:59:59+00:00"
generated_at: "2026-06-28T18:11:57.878683+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lilly Q3 revenue up 18% to $6.77B; non-GAAP EPS $1.94 (+38%); pipeline advances with tirzepatide, donanemab

## Summary
- Q3 revenue $6.773B (+18% YoY); GAAP EPS $1.22 (-8%), non-GAAP EPS $1.94 (+38%).
- Key growth products (Trulicity +45%, Verzenio +43%) drove 17pp of growth; COVID-19 antibody revenue $423.5M.
- Submitted tirzepatide NDA for type 2 diabetes with priority review voucher; initiated rolling submission for donanemab in early Alzheimer's.
- FDA approved Verzenio for high-risk early breast cancer and Jardiance for HFrEF; positive Phase 3 for lebrikizumab in atopic dermatitis.
- Repurchased higher-cost debt ($405.2M charge); issued €600M sustainability bond.

## SEC filing metadata
- accession: 0000059478-21-000213
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2021-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947821000213/0000059478-21-000213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947821000213/lly-20211026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-21-000213
- JSON: https://secwatch.observer/filing/0000059478-21-000213.json
- Plain text: https://secwatch.observer/filing/0000059478-21-000213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.